Literature DB >> 25820290

Antimicrobial susceptibility of rapidly growing mycobacteria using the rapid colorimetric method.

I B Ramis1, M Cnockaert, A von Groll, C L Nogueira, S C Leão, E Andre, A Simon, J C Palomino, P E A da Silva, P Vandamme, A Martin.   

Abstract

Drug susceptibility testing (DST) of rapidly growing mycobacteria (RGM) are recommended for guiding the antimicrobial therapy. We have evaluated the use of resazurin in Mueller-Hinton medium (MHR) for MIC determination of RGM and compared the results with those obtained with the reference standard broth microdilution in Mueller-Hinton (MH) and with the resazurin microtiter assay (REMA) in 7H9 broth. The MIC of eight drugs: amikacin (AMI), cefoxitin (FOX), ciprofloxacin (CIP), clarithromycin (CLA), doxycycline (DOX), linezolid (LZD), moxifloxacin (MXF) and trimethoprim-sulfamethoxazole (TMP-SMX) were evaluated against 76 RGM (18 species) using three methods (MH, MHR, and REMA) in a 96-well plate format incubated at 37 °C over 3-5 days. Results obtained in the MH plates were interpreted by the appearance of turbidity at the bottom of the well before adding the resazurin. MHR and 7H9-REMA plates were read by visual observation for a change in color from blue to pink. The majority of results were obtained at day 5 for MH and 1 day after for MHR and 7H9-REMA. However, the preliminary experiment on time to positivity results using the reference strain showed that the resazurin can be added to the MH at day 2 to produce the results at day 3, but future studies with large sets of strains are required to confirm this suggestion. A high level of agreement (kappa 1.000-0.884) was obtained between the MH and the MHR. Comparison of results obtained with 7H9-REMA, on the other hand, revealed several discrepancies and a lower level of agreement (kappa 1.000-0.111). The majority of the strains were resistant to DOX and TMP-SMX, and the most active antimicrobials for RGM were AMI and FOX. In the present study, MHR represented an excellent alternative for MIC determination of RGM. The results could be read reliably, more easily, and more quickly than with the classical MH method.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25820290     DOI: 10.1007/s10096-015-2365-2

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  22 in total

1.  Clinical significance and antibiotic susceptibilities of nontuberculous mycobacteria from patients in Crete, Greece.

Authors:  Zoe Gitti; Elpis Mantadakis; Sofia Maraki; George Samonis
Journal:  Future Microbiol       Date:  2011-09       Impact factor: 3.165

2.  Antibiotic susceptibility pattern of rapidly growing mycobacteria.

Authors:  R Gayathri; K Lily Therese; P Deepa; S Mangai; H N Madhavan
Journal:  J Postgrad Med       Date:  2010 Apr-Jun       Impact factor: 1.476

Review 3.  Laboratory aspects of clinically significant rapidly growing mycobacteria.

Authors:  R Set; J Shastri
Journal:  Indian J Med Microbiol       Date:  2011 Oct-Dec       Impact factor: 0.985

4.  In vitro antibiotic susceptibility of rapidly growing nontuberculous mycobacteria isolated from patients with microbial keratitis.

Authors:  Ashok Kumar Reddy; Prashant Garg; K Hari Babu; Usha Gopinathan; Savitri Sharma
Journal:  Curr Eye Res       Date:  2010-03       Impact factor: 2.424

5.  Pulmonary disease caused by rapidly growing mycobacteria: a retrospective study of 44 cases in Japan.

Authors:  Yukihiro Yano; Seigo Kitada; Masahide Mori; Shinichi Kagami; Takahiro Taguri; Takeshi Uenami; Yoshinobu Namba; Tsutomu Yoneda; Soichiro Yokota; Ryoji Maekura
Journal:  Respiration       Date:  2012-08-11       Impact factor: 3.580

6.  Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of nontuberculous mycobacteria.

Authors:  Richard J Wallace; Barbara A Brown-Elliott; Christopher J Crist; Linda Mann; Rebecca W Wilson
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

7.  Resazurin microtiter assay plate: simple and inexpensive method for detection of drug resistance in Mycobacterium tuberculosis.

Authors:  Juan-Carlos Palomino; Anandi Martin; Mirtha Camacho; Humberto Guerra; Jean Swings; Françoise Portaels
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

8.  Resazurin microtiter assay plate testing of Mycobacterium tuberculosis susceptibilities to second-line drugs: rapid, simple, and inexpensive method.

Authors:  Anandi Martin; Mirtha Camacho; Françoise Portaels; Juan Carlos Palomino
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

9.  In Vitro Antimicrobial Susceptibility of Mycobacterium massiliense Recovered from Wound Samples of Patients Submitted to Arthroscopic and Laparoscopic Surgeries.

Authors:  Alessandra Marques Cardoso; Ana Paula Junqueira-Kipnis; André Kipnis
Journal:  Minim Invasive Surg       Date:  2011-01-04

10.  Skin and Soft Tissue Infection due to Rapidly Growing Mycobacteria: Case Series and Literature Review.

Authors:  Jung Re Yu; Sang Taek Heo; Keun Hwa Lee; Jinseok Kim; Jae Kyung Sung; Young Ree Kim; Jae Wang Kim
Journal:  Infect Chemother       Date:  2013-03-29
View more
  3 in total

1.  Resazurin Microtiter Assay for Clarithromycin Susceptibility Testing of Clinical Isolates of Mycobacterium abscessus Group.

Authors:  Natalia Fernandes Garcia de Carvalho; Daisy Nakamura Sato; Fernando R Pavan; Lucilaine Ferrazoli; Erica Chimara
Journal:  J Clin Lab Anal       Date:  2016-05-12       Impact factor: 2.352

2.  Evaluation of crystal violet decolorization assay and resazurin microplate assay for antimycobacterial screening.

Authors:  Maya Dian Rakhmawatie; Tri Wibawa; Puspita Lisdiyanti; Woro Rukmi Pratiwi
Journal:  Heliyon       Date:  2019-08-28

3.  Rifamycin O, An Alternative Anti-Mycobacterium abscessus Agent.

Authors:  Bui Thi Bich Hanh; June-Woo Park; Tae Ho Kim; Jae-Sung Kim; Chul-Su Yang; Kiseok Jang; Jinsheng Cui; Dong-Chan Oh; Jichan Jang
Journal:  Molecules       Date:  2020-03-31       Impact factor: 4.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.